Latest Intelligence on Pharmaceuticals and Healthcare in Switzerland

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Sulzer Medica: shareholders revolt

Sulzer Medica faces a growing revolt from investors over its latest attempt to protect its US subsidiary from obligators over the withdrawal of Inter-Op shells. Sulzer needs to answer the criticisms being voiced against it and address the uncertainty surrounding the tibial baseplate recall, or it risks losing even more investor confidence.

Published By Datamonitor
14 Nov 2001
CommentWire
CommentWire

Roche/Chugai: pharmaceuticals consolidation reaches Japan

The Swiss pharmaceutical giant Roche arose from slumber earlier this week, announcing its merger with Chugai. Although the move will benefit both Roche and Chugai, and marks an important milestone in the globalization of the industry in Japan, Roche still needs to do more to accelerate its growth and catch up with its peers.

Published By Datamonitor
12 Dec 2001
CommentWire
CommentWire

Sulzer Medica: one year later, still fighting

A year ago, few could have expected the effects of Sulzer Medica's voluntary recall would be so serious. If individual settlements are allowed, the medical devices manufacturer is likely to go bankrupt. Even if it can negotiate a settlement, it will have to pay as much as $783 million - and then face the challenge of rebuilding its reputation.<BR />

Published By Datamonitor
14 Dec 2001
CommentWire
CommentWire

Novartis: dropping the healthy eating kick

Novartis wants to focus on its core higher-margin pharmaceutical business. But while the units may be Novartis's cast-offs, they are still top performers in the high-growth functional food market. This leaves them sure to attract a number of potential buyers, with Nestle and Danone the frontrunners.

Published By Datamonitor
05 Feb 2002
CommentWire
CommentWire

Novartis: strong 2001, thanks to CNS success

The Swiss group's sales climbed 14% when measured in local currencies. Much of this growth came from sales of CNS drugs, due both to Novartis' strong portfolio and its heavy marketing initiatives in the US. Looking ahead, developing the pipeline and investing still further in the US business would be the most sensible route for Novartis to follow.

Published By Datamonitor
07 Feb 2002
CommentWire
CommentWire

Sulzer: paying big to save its reputation

The settlement comes nearly fifteen months after Sulzer Medica voluntarily recalled its defective acetabular hip cup. Sulzer hopes that the $200,000 compensation each patient is due to receive will enable it to move on, and the $1 billion sum will be enough to reward all affected patients. However, rebuilding its reputation will not be easy.

Published By Datamonitor
07 Feb 2002
CommentWire
CommentWire

Roche: hoping for a better 2002

Much of the fall was due to the troubled vitamin and fine chemicals division, which Roche may well sell this year. However, the pharmaceutical division also had problems. Things may be better 2002, within the cardiovascular sphere at least. If weight loss drug Xenical is approved in type 2 diabetics, the market potential will be considerable.

Published By Datamonitor
01 Mar 2002
CommentWire
CommentWire

Serono: the future is bright with Rebif

The regulator's decision to break the orphan drug status of Biogen's Avonex and allow Rebif's US sale is a massive boost to Serono's growth prospects. The resulting extra revenues should allow Serono to increase its comparatively weak pipeline through in-licensing deals - and also by going on the acquisition trail.

Published By Datamonitor
13 Mar 2002
CommentWire
CommentWire

Novartis: Glivec leaves Brits unconvinced

Despite Novartis' chronic myeloid leukemia drug Glivec gaining fast-track approval in Europe, NICE has decided to limit its use in CML patients to the accelerated phase only. The watchdog's reason was the lack of cost-effective data, showing that pharma companies need to ensure their clinical trials highlight this factor convincingly.

Published By Datamonitor
15 May 2002
CommentWire
CommentWire

Novartis: good results from three Lotrel trials

Lotrel demonstrated positive results in various hard-to-treat hypertensive patient groups. This places Novartis' drug in an advantageous position compared to the market leading single compound antihypertensive, Pfizer's Norvasc. If forthcoming trial results in African-Americans prove similarly positive, the drug's sales should be stronger still.

Published By Datamonitor
17 May 2002

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.